The worldwide market for attention-deficit hyperactivity disorder (ADHD) will grow from the $14 billion 2015 valuation to $25 billion by 2024, says a new report from Persistence Market Research.
Revenue in this market is expected to expand at a compound annual growth rate (CAGR) of 6.2% over that period, the research firm predicts.
Its report finds that the sub-segment of lisdexamfetamine dimesylate, which is sold by Ireland-incorporated drugmaker Shire (LSE: SHP) as Vyvanse, is anticipated to register the highest CAGR of 15.6% in terms of value over the forecast period.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze